Close Menu

Tekmira Pharmaceuticals said last week that it has stopped a phase I study of its siRNA-based hypercholesterolemia drug ApoB SNALP.

While the drug was well tolerated and showed some signs of clinical activity, Tekmira said that it has put the phase I program on hold in order to select a new siRNA and drug-delivery formulation for development. The new agent is expected to be "several-fold more potent than the current formulation," the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Washington Post reports that the CDC's SARS-CoV-2 test issues reflect earlier ones it had with Zika virus testing.

Researchers traced a gene cluster linked to COVID-19 severity to Neanderthals, the New York Times reports.

NPR writes that even with thousands of new COVID-19 papers, each should be evaluated based on its own quality.

In PNAS this week: soil bacteria-derived small molecules affect centrosomal protein, microfluidics approach for capturing circulating tumor cells, and more.